{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:06:42Z","timestamp":1784858802431,"version":"3.55.0"},"reference-count":13,"publisher":"Innovative Healthcare Institute","issue":"3","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,23]]},"DOI":"10.36401\/jipo-26-5","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:34:16Z","timestamp":1784856856000},"page":"120-123","source":"Crossref","is-referenced-by-count":0,"title":["ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6"],"prefix":"10.36401","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0790-9861","authenticated-orcid":true,"given":"Atlal","family":"Abusanad","sequence":"first","affiliation":[{"name":"Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Medical Oncology Division, Department of medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","reference":[{"key":"i2590-017X-9-3-120-b01","series-title":"N Engl J Med","first-page":"1925","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","unstructured":"Finn RS,\nMartin M,\nRugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u20131936. DOI: 10.1056\/NEJMoa1607303"},{"key":"i2590-017X-9-3-120-b02","series-title":"JCO","first-page":"3638","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","unstructured":"Goetz MP,\nToi M,\nCampone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. JCO. 2017;35:3638\u20133646. DOI: 10.1200\/JCO.2017.75.6155"},{"key":"i2590-017X-9-3-120-b03","series-title":"N Engl J Med","first-page":"942","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","unstructured":"Hortobagyi GN,\nStemmer SM,\nBurris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942\u2013950. DOI: 10.1056\/NEJMoa2114663"},{"key":"i2590-017X-9-3-120-b04","series-title":"Nat Rev Clin Oncol","first-page":"573","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","unstructured":"Jeselsohn R,\nBuchwalter G,\nDe Angelis C,\nBrown M,\nSchiff R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573\u2013583. DOI: 10.1038\/nrclinonc.2015.117"},{"key":"i2590-017X-9-3-120-b05","series-title":"Clin Cancer Res","first-page":"3433","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2\u2212 ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","unstructured":"Cristofanilli M,\nRugo HS,\nIm SA, et al. Overall survival with palbociclib and fulvestrant in women with HR+\/HER2\u2212 ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clin Cancer Res. 2022;28:3433\u20133442. DOI: 10.1158\/1078-0432.CCR-22-0305"},{"key":"i2590-017X-9-3-120-b06","series-title":"Lancet","first-page":"2997","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone-receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","unstructured":"Robertson JFR,\nBondarenko IM,\nTrishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone-receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388:2997\u20133005. DOI: 10.1016\/S0140-6736(16)32389-3"},{"key":"i2590-017X-9-3-120-b07","series-title":"JCO","first-page":"1664","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","unstructured":"Chia S,\nGradishar W,\nMauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. JCO. 2008;26:1664\u20131670. DOI: 10.1200\/JCO.2007.13.5822"},{"key":"i2590-017X-9-3-120-b08","series-title":"JCO","first-page":"4594","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","unstructured":"Di Leo A,\nJerusalem G,\nPetruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. JCO. 2010;28:4594\u20134600. DOI: 10.1200\/JCO.2010.28.8415"},{"key":"i2590-017X-9-3-120-b09","series-title":"JCO","first-page":"3246","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","unstructured":"Bidard FC,\nKaklamani VG,\nNeven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMERALD trial. JCO. 2022;40:3246\u20133256. DOI: 10.1200\/JCO.22.00338"},{"key":"i2590-017X-9-3-120-b10","series-title":"N Engl J Med","first-page":"1189","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","unstructured":"Jhaveri KL,\nNeven P,\nCasalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189\u20131202. DOI: 10.1056\/NEJMoa2410858"},{"key":"i2590-017X-9-3-120-b11","series-title":"Lancet Oncol","first-page":"1367","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","unstructured":"Bidard FC,\nHardy-Bessard AC,\nDalenc F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23:1367\u20131377. DOI: 10.1016\/S1470-2045(22)00555-1"},{"key":"i2590-017X-9-3-120-b12","series-title":"N Engl J Med","first-page":"569","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Huang-Bartlett","year":"2025","unstructured":"Huang-Bartlett C,\nTurner NC,\nBidard FC, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025;393:569\u2013580. DOI: 10.1056\/NEJMoa2502929"},{"key":"i2590-017X-9-3-120-b13","series-title":"Ann Oncol","first-page":"180","article-title":"Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4\/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy","volume":"37","author":"Mayer","year":"2026","unstructured":"Mayer EL,\nBidard FC,\nPark YH, et al. Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4\/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy. Ann Oncol. 2026;37:180\u2013193. DOI: 10.1016\/j.annonc.2025.10.006"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"link":[{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/3\/article-p120.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/3\/article-p120.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/3\/article-p120.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:34:16Z","timestamp":1784856856000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/3\/article-p120.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":13,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.36401\/jipo-26-5","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}